Bipartisan Momentum or Radical Reform? Insiders Weigh In on the Future of Psychedelic Research and Regulation Under Trump or Harris Post published:November 4, 2024 Post category:Analysis/News/Pα+
Pα+ Psychedelic Bulletin #179: VA Funds MDMA for PTSD and AUD Study, Chooses Low-Dose MDMA as Control; A Look at the Latest Oregon Psilocybin Services Complaints Post published:November 1, 2024 Post category:Psychedelic Bulletin/Pα+
Backed by $15m in NIDA Funding, NYU and B.More Team Up to Trial Psilocybin for Opioid Use Disorder Post published:October 31, 2024 Post category:Analysis/News/Pα+
Compass Pathways Pushes Back Phase 3 Readouts, Lays Off 30% of Staff Post published:October 31, 2024 Post category:Analysis/News/Pα+
Pα+ Psychedelic Bulletin #178: VA Funding of Lykos Phase 3 ‘Definitely a Possibility’; Alto’s Precision Psychiatry Platform Under Pressure; MAPS Boosts Funding for Mass. Psychedelics Ballot Question Post published:October 25, 2024 Post category:Psychedelic Bulletin/Pα+
Pα+ Psychedelic Bulletin #177: Bright Minds Surges on Longboard’s Seizure Drug Success; Kasvu Therapeutics Is Developing Psychoplastogens With a TrkB Twist Post published:October 18, 2024 Post category:Psychedelic Bulletin/Pα+
Pα+ Psychedelic Bulletin #176: Drug Developers Discuss Trial Design; Massachusetts Vote is Too Close to Call as Last-Minute Donations Flow In; SEC Charges ‘Pump and Dump’ Scheme Post published:October 11, 2024 Post category:Psychedelic Bulletin/Pα+
Pα+ Psychedelic Bulletin #175: atai Sells a Third of Compass Stake; Lykos’ Unproven Psychotherapy Hampered Studies, Claim Academics; Picking Placebos Post published:October 4, 2024 Post category:Psychedelic Bulletin/Pα+
The Psychedelics Lobby: Tracking Federal Lobbying by Psychedelics Companies and Nonprofits Post published:September 30, 2024 Post category:Analysis/News/Pα+